-+ 0.00%
-+ 0.00%
-+ 0.00%

Kazia expands Phase 1b paxalisib trial in advanced triple-negative breast cancer to 36 patients

PUBT·05/26/2026 11:31:16
Listen to the news
Kazia expands Phase 1b paxalisib trial in advanced triple-negative breast cancer to 36 patients
  • Kazia Therapeutics expanded its Phase 1b paxalisib combination trial in advanced triple-negative breast cancer, lifting planned enrollment to 36 from 12.
  • The move follows encouraging safety, tolerability, and early clinical activity signals, supporting continued dose refinement and a clearer efficacy read.
  • Scientific results were not presented at ASCO 2026; abstracts were withdrawn for intellectual property reasons, not due to safety concerns.
  • Additional clinical updates are expected through 2026 into 2027, a key catalyst window for the program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN67393) on May 26, 2026, and is solely responsible for the information contained therein.